Autolus Therapeutics vs Cellectis
Autolus Therapeutics reported revenue of $75 million in fiscal 2025, about the same as Cellectis' $73 million in fiscal 2025. Autolus Therapeutics' revenue grew 644.9% in its latest year, and Cellectis' grew 75.8%. Autolus Therapeutics had an operating margin of -358.9%, against -45.3% at Cellectis. Free cash flow was −$303 million at Autolus Therapeutics and −$42 million at Cellectis.
Side by side
| Autolus Therapeutics | Cellectis | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $75M | $73M |
| Revenue growth | 644.9% | 75.8% |
| Revenue growth a year, last 5 years | — | 7.4% |
| Gross margin | −27.8% | 100.0% |
| Operating margin | −358.9% | −45.3% |
| Net margin | −381.4% | −92.7% |
| Free cash flow | −$303M | −$42M |
| Free cash flow margin | −401.4% | −57.2% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 4.3% | 10.7% |
| Last close | $0.98 | $0.98 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $15,708 | — |
| Piotroski F-score | 3 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Autolus TherapeuticsCellectis
Operating margin
Percent of revenue
Autolus TherapeuticsCellectis
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Autolus TherapeuticsCellectis
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Autolus Therapeutics and Cellectis pages.